Stephen Henry Gillespie

Search results

• Active

  Unite4TB H2020: Unite4TB: Academia and industry united innovation and treatment for tuberculosis

  Gillespie, S. H. (PI), Sabiiti, W. (CoI) & Sloan, D. J. (CoI)

  European Commission

  1/06/21 → 1/05/25

  Project: Standard

  • Drug Development 100%
  • Drug Screening 50%
  • Biological Marker 50%
  • Tuberculosis Treatment 50%
  • Patient Monitoring 50%

• EDCTP TRIAD: EDCTP - TRIAD

  Gillespie, S. H. (PI)

  1/01/21 → 31/12/24

  Project: Standard

  • Clinical Trial 100%
  • Anti-biotics 66%
  • Antibiotic Resistance 66%
  • Cross Sectional Study 66%
  • Clinical Study 66%
• Finished

  EQATA: EQATA: Equitable access to Quality Antibiotic Therapies in Africa

  Gillespie, S. H. (PI)

  EPSRC

  1/04/20 → 31/03/22

  Project: Standard

• SimpliciTB - S Gillespie: EDCTP SimpliciTB 2018

  Gillespie, S. H. (PI)

  European and Developing Countries

  1/01/19 → 31/12/22

  Project: Standard

  • Pyrazinamide 100%
  • Pretomanid 100%
  • Moxifloxacin 100%
  • Tuberculosis Treatment 50%
  • Drug Resistant Tuberculosis 50%

• Wilber Sabiiti - SFC ODA 18/19: Scotland - West Africa partnership to fight Antimicrobial resistance (SWAB)

  Sabiiti, W. (PI), Gillespie, S. H. (CoI) & Holden, M. (CoI)

  Scottish Funding Council

  1/12/18 → 30/06/19

  Project: Standard

• Wilbur Sabiiti - SFC ODA 18/19: Tackling Antimicrobial Resistance in Low and Middle-Income Countries (LMICs)

  Sabiiti, W. (PI), Gillespie, S. H. (CoI) & Sloan, D. J. (CoI)

  Scottish Funding Council

  1/09/18 → 30/06/19

  Project: Standard

  • Biological Marker 100%
  • Rifampicin 100%
  • Ethambutol 50%
  • Isoniazid 50%
  • Pyrazinamide 50%

• Stephen Gillespie - SFC ODA 18/19: Tackling Antimicrobial Resistance in Low and Middle-Income Countries (LMICs): Taking St Andrews University innovation to worldwide application’

  Gillespie, S. H. (PI), Sabiiti, W. (CoI) & Sloan, D. J. (CoI)

  Scottish Funding Council

  1/08/18 → 30/06/19

  Project: Standard

• SLIC: SLIC: a feasibility study of a novel rapid diagnostic test fo uncomplicated urinary tract infections in primary care

  Gillespie, S. H. (PI), Hammond, R. (CoI), Hernandez Santiago, V. (CoI) & Sullivan, F. (CoI)

  1/07/18 → 31/12/19

  Project: Standard

• Prof M Holden MRC: Holistic approach to unravel antibacterial resistance in East Africa (HATUA)

  Holden, M. (PI), Gillespie, S. H. (CoI), Keenan, K. L. (CoI), Kesby, M. (CoI), Lynch, A. (CoI), Sabiiti, W. (CoI), Sloan, D. J. (CoI) & Smith, V. A. (CoI)

  Medical Research Council

  1/05/18 → 30/04/21

  Project: Standard

  • Urinary Tract Infection 100%
  • Antibiotic Resistance 85%
  • Antibiotics 76%
  • Escherichia coli 70%
  • Urinary Tract 70%

• SMART Centre: St Andrews Multidisciplinary Anti-infective Research and Therapeutics Centre SMART Centre

  Goss, R. (PI) & Gillespie, S. H. (CoI)

  1/03/18 → 31/10/20

  Project: Standard

  • Chemistry 100%
  • Polypeptide Antibiotic Agent 100%
  • Pictet-Spengler Synthesis 100%
  • Diastereomer 50%

• Prof M Holden - MRC: Holistic Approach Towards Unravelling Antibiotic Resistance in East Africa

  Holden, M. (PI), Gillespie, S. H. (CoI), Kesby, M. (CoI), Lynch, A. (CoI), Sabiiti, W. (CoI), Sloan, D. J. (CoI) & Thomas, L. (CoI)

  Medical Research Council

  1/11/17 → 30/06/18

  Project: Standard

• Tackling Antimicrobial Resistance: Tackling Antimicrobial Resistance in Low and Middle-Income Countries (LMIC's): Taking St Andrews University innovation to worldwide application

  Gillespie, S. H. (PI), Sabiiti, W. (CoI) & Sloan, D. J. (CoI)

  Scottish Funding Council

  1/10/17 → 31/03/18

  Project: Standard

• Lindsey Karmen Vacation Scholarship: Molecular viable count testing in Pseudomonas chronic bronchial infection

  Gillespie, S. H. (PI)

  The Wellcome Trust

  1/06/16 → 26/07/16

  Project: Studentship

• IMI PREDICT TB 100%: IMI Pre-DiCT-TB

  Gillespie, S. H. (PI)

  European Commission

  1/05/12 → 31/10/17

  Project: Standard

  • Mycobacterium Tuberculosis 100%
  • Sputum 94%
  • Rifampicin 83%
  • Drug Development 54%
  • Pharmacokinetics 50%

• IMI PREDICT TB: EU Innovative Medicines Initiative (IMI) 75% account

  Gillespie, S. H. (PI)

  European Commission

  1/05/12 → 31/10/17

  Project: Standard

  • Bacterial Load 100%
  • Mycobacterium Tuberculosis 82%
  • Infection 78%
  • Infectious Agent 67%
  • Perfusion 61%

• Rapid Evolution of Biomarkers: Rapid Evaluation of Biomarkers in Tuberculosis

  Gillespie, S. H. (PI)

  Medical Research Council

  1/07/11 → 31/10/11

  Project: Standard

  • Drug Efficacy 100%
  • Sputum 100%
  • Mycobacterium Tuberculosis 100%
  • Drug Therapy 71%
  • Pharmacotherapy 71%

• GCVX MRC G0802079: GCVX MRC G0802079

  Gillespie, S. H. (PI)

  Medical Research Council

  1/05/11 → 30/04/12

  Project: Standard

• EU FP7 PAR: EU FP7 PAR

  Gillespie, S. H. (PI)

  European Commission

  1/08/10 → 31/03/13

  Project: Standard